Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

What to Expect From Amgen's Next Quarterly Earnings Report

With a market cap of $191.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics for a wide range of diseases, including cancer, cardiovascular conditions, and autoimmune disorders. It markets leading medicines such as Enbrel, Prolia, and Repatha while collaborating with partners like AstraZeneca plc and UCB to expand its pipeline and global reach.

The Thousand Oaks, California-based company is expected to release its fiscal Q1 2026 results after the market closes on Thursday, Apr. 30. Ahead of this event, analysts expect AMGN to report an adjusted EPS of $4.75, down 3.1% from $4.90 in the prior year's quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.